Page de couverture de Prasad Kulkarni on dengue monoclonal antibodies

Prasad Kulkarni on dengue monoclonal antibodies

Prasad Kulkarni on dengue monoclonal antibodies

Écouter gratuitement

Voir les détails du balado

À propos de cet audio

Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue control and drug development.

Read the full article:
https://www.thelancet.com/journals/laninf/article/ S1473-3099(24)00030-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laninf

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Ce que les auditeurs disent de Prasad Kulkarni on dengue monoclonal antibodies

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.